Back to Results
First PageMeta Content
Ribbon symbolism / Trastuzumab / Adjuvant therapy / Breast cancer / Management of cancer / End point of clinical trials / Triple-negative breast cancer / Neoadjuvant therapy / MammaPrint / Medicine / Cancer treatments / Oncology


The NEW ENGLA ND JOURNAL of
Add to Reading List

Document Date: 2012-06-05 13:00:31

Open Document

File Size: 388,78 KB

Share Result on Facebook

City

Baltimore / /

Company

The New England Journal / Hess / /

Country

United States / /

Event

FDA Phase / /

Facility

Johns Hopkins University / /

IndustryTerm

treatment for early-stage breast cancer / cancer therapies / cancer treatment / /

MedicalCondition

ER- and PRpositive tumors / residual tumor / early-stage breast cancer / operable HER2-positive breast cancer / localized breast cancer / HER2-positive locally advanced breast cancer / ER- or PR-positive tumors / early-stage disease / locally advanced cancers / metastatic disease / ER- and PR-negative tumors / high-grade tumors / distant metastatic disease / Early Breast Cancer Tatiana M. Prowell / Breast Cancer cancer / High-Risk Early-Stage Breast Cancer / operable breast cancer / HER2positive breast cancer / ER- and PR-positive tumors / triple-negative breast cancer / intrinsic breast cancer / curable disease / residual invasive cancer / breast cancer / curable cancer / /

MedicalTreatment

neoadjuvant therapy / adjuvant chemotherapy / Neoadjuvant Treatment / chemotherapy / surgery / breast-cancer therapies / /

Organization

National Institute of Health / office of Hematology Oncology Products / Food and Drug Administration / Johns Hopkins University / Comprehensive Cancer Center / Massachusetts Medical Society / /

Person

Silver Spring / Richard Pazdur / /

Product

Early Breast Cancer / UCM305501 / /

ProvinceOrState

Massachusetts / /

PublishedMedium

The NEW ENGLA ND JOURNAL / The New England Journal / /

Technology

chemotherapy / pdf / /

URL

www.fda.gov/downloads / /

SocialTag